Medication-assisted treatment (MAT) and opioid treatment programs (OTPs) use drug testing for two distinct jobs: confirming that a patient's prescribed medication (buprenorphine or methadone) is actually present, and screening for non-prescribed substances that signal relapse or a safety risk. Federal rule requires OTPs to run at least eight random drug tests per patient per year using FDA-authorized tests (42 CFR 8.12(f)(6)). Because a standard opiate immunoassay is not built to catch buprenorphine or methadone, programs generally need to add medication-specific panels alongside their illicit-drug screen. This article covers what that testing actually verifies, the regulatory floor programs must meet, and the cup and panel configurations treatment centers order to cover it. It does not offer clinical or treatment advice; it is a supply and program-design guide for procurement staff.
What drug testing does in a MAT or OTP program
Programs treating opioid use disorder with buprenorphine, methadone, or naltrexone lean on urine testing for two separate purposes, and mixing them up leads to the wrong panel getting ordered.
- Medication adherence. For buprenorphine and methadone, both controlled substances with diversion risk, a testing program needs to confirm the patient is actually taking the dose prescribed rather than selling or trading it. This requires a panel built to detect that specific medication and its metabolite, not a generic opiate strip.
- Non-prescribed substance use. The same testing event also screens for illicit or non-prescribed drugs, fentanyl, cocaine, benzodiazepines, amphetamines, and synthetic cannabinoids among them, that can complicate treatment, indicate relapse, or create an overdose risk when combined with the prescribed medication.
- Naltrexone is different. Naltrexone is an opioid antagonist with no misuse or diversion potential, so programs generally do not run adherence testing for naltrexone itself. Toxicology in naltrexone-based programs still matters, though, because it screens for the opioid or other substance use the medication is meant to help prevent.
The federal testing floor: 42 CFR Part 8
SAMHSA's regulations for opioid treatment programs are set out in 42 CFR Part 8. Under 42 CFR 8.12(f)(6), an OTP running random drug testing "must use drug tests that have received the Food and Drug Administration's (FDA) marketing authorization for commonly used and misused substances that may impact patient safety, recovery, or otherwise complicate substance use disorder treatment," at a frequency tied to clinical practice and patient stability, "but no fewer than eight random drug tests per year patient." (42 CFR 8.12)
This is the current version of the rule following SAMHSA's 2024 overhaul of Part 8, published in the Federal Register on February 2, 2024, effective April 2, 2024, with a compliance date of October 2, 2024. That rulemaking was the first comprehensive update to OTP standards in more than two decades and reset multiple program requirements, testing frequency among them. (Federal Register, 2024-01693)
Two things fall out of that text for a buyer. First, the eight-test floor is a minimum, not a target; most programs test more often, especially early in treatment. Second, the tests used have to carry FDA marketing authorization, which rules out building a program around unverified or off-label devices.
Why buprenorphine and methadone need their own panels
A standard workplace-style opiate immunoassay is built to catch morphine, codeine, and heroin metabolites. It is not built to catch buprenorphine or methadone, because those are semisynthetic and synthetic opioids with a different chemical structure that the standard opiate antibody does not reliably cross-react with. A federal five-panel opiate screen "includes opiates (including heroin, morphine, and codeine, but not synthetic opioids such as oxycodone, hydrocodone, buprenorphine, or methadone)." (PMC, Objective Testing: Urine and Other Drug Tests) That is exactly why treatment centers order separate, medication-specific cups or dip cards rather than relying on a generic opiate strip to do double duty.
It also cuts the other way. Published research on directly observed buprenorphine dosing has found that a meaningful share of confirmed-adherent patients can still test negative for buprenorphine on lab confirmation, most often when the patient is also taking another medication that speeds up how the body clears buprenorphine. The study's authors are explicit that a negative result on its own "does not betoken nonadherence to treatment." (PubMed 34520028) The practical takeaway for procurement is that a program needs the right panel to get a meaningful result in the first place, and that interpreting any single result is a clinical decision, not a supply decision.
Cup and panel configurations treatment centers order
Most OTPs and MAT clinics build their testing around a base illicit-drug panel plus one or more medication-specific and threat-specific add-ons, commonly labeled by abbreviation on the cup or dip card:
- BUP (buprenorphine), to confirm the prescribed medication is present.
- MTD (methadone), the equivalent adherence check for methadone-maintenance patients.
- FEN (fentanyl), added given how much illicit fentanyl has displaced heroin in the drug supply; a standard opiate panel will not flag it either.
- A base panel of commonly misused substances (amphetamines, cocaine, benzodiazepines, THC, and similar), plus adulterant checks (pH, creatinine, oxidant, specific gravity) to help flag a diluted or substituted sample before it reaches the lab.
Programs typically combine these into one multi-panel cup rather than running separate devices, since a single cup that reads BUP, MTD, FEN, and a standard panel in one collection cuts both collection time and per-visit cost. ASC's multi-panel drug test cup collection and its rehabilitation and addiction treatment center drug testing collection are built around exactly that kind of configuration work.
Standard panel vs. MAT-specific panel
| Panel component | What it targets | Detects buprenorphine or methadone? | Typical role in a MAT/OTP program |
|---|---|---|---|
| Standard opiate strip (OPI) | Morphine, codeine, heroin metabolite | No | General illicit-opioid screening only |
| BUP strip | Buprenorphine and its metabolite | Buprenorphine, yes | Medication adherence for buprenorphine patients |
| MTD strip | Methadone and its metabolite | Methadone, yes | Medication adherence for methadone patients |
| FEN strip | Fentanyl and its metabolite | No (separate analyte) | Illicit fentanyl exposure and overdose-risk screening |
| Base multi-drug panel | Amphetamines, cocaine, benzodiazepines, THC, and similar | No | Non-prescribed substance screening / relapse indicators |
Building a compliant, cost-controlled program
Because the federal floor sets a minimum test count rather than a fixed protocol, most of the program design work is about matching panel configuration to caseload and keeping per-test cost predictable across a patient roster that can run from dozens to hundreds of people. That is a procurement and clinical-operations conversation more than a testing-technology one, and it is covered in more depth in ASC's guide on what treatment centers should look for in a drug test supplier.
One more piece worth planning for up front: any non-negative screen on a cup or dip card is a presumptive result, not a confirmed positive, and needs lab confirmation before it is treated as one. ASC's article on what lab confirmation does after a non-negative screen walks through that second step, which matters for MAT programs given how often a false or borderline non-negative can occur around medication metabolites.
Frequently asked questions
Do medication-assisted treatment programs have to drug test patients?
Yes. Under 42 CFR 8.12(f)(6), opioid treatment programs running random drug testing must use FDA-authorized tests at a frequency of no fewer than eight random tests per patient per year, adjusted based on clinical practice and the patient's stability in treatment.
Will a standard opiate test show a positive result for buprenorphine or methadone?
No. Standard opiate immunoassays are built to detect morphine, codeine, and heroin metabolite. They are not designed to reliably detect buprenorphine or methadone, which require their own dedicated test panels.
Why do treatment centers order fentanyl-specific panels separately from a standard opiate panel?
Because a standard opiate strip does not detect fentanyl either. Given how much illicit fentanyl has entered the drug supply, most treatment centers add a dedicated fentanyl (FEN) panel to their cups rather than relying on the base opiate strip to catch it.
What happens after a non-negative screen in a MAT program?
A non-negative result on a cup or dip card is presumptive, not confirmed. It should go to lab-based confirmation testing (chromatography paired with mass spectrometry) before the result is treated as positive or used in a clinical decision.
How often should an OTP test patients?
Federal rule sets a floor of no fewer than eight random drug tests per patient per year. Actual frequency is set according to generally accepted clinical practice and the individual patient's response to and stability in treatment, so many programs test more often than the floor, particularly early in treatment.
Does naltrexone treatment require the same adherence testing as buprenorphine or methadone?
No. Naltrexone has no misuse or diversion potential, so programs typically do not run a naltrexone-specific adherence panel. Toxicology testing in naltrexone-based programs still matters for screening the opioid or other substance use the medication is intended to help prevent.
Compliance note
This article is a supply and testing-program reference for procurement and operations staff, not clinical or medical guidance. Drug test cups, dip cards, and similar devices are screening tools; a non-negative result is presumptive and requires laboratory confirmation before any clinical or administrative action is taken. Program design, testing frequency above the federal floor, and interpretation of results should be set by qualified clinical staff in line with 42 CFR Part 8 and applicable state requirements.
